

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1-12(Cancelled).

13(Currently Amended): The formulation according to claim 31, wherein the alcoholic solvent is ethanol, propylene glycol, polyethylene glycol 300, polyethylene glycol 400, polyethylene glycol 600, or mixtures thereof~~polyethylene glycol 1000~~.

14(Currently Amended): The formulation according to claim 31, wherein the antioxidant further comprises citric acid, glycine, BHA, BHT, monothioglycerol, ascorbic acid, or propyl gallate.

15(Currently Amended): The formulation according to claim 31, wherein the diluent solvent is water, ethanol, polyethylene glycol 300, polyethylene glycol 400, polyethylene glycol 600, ~~polyethylene glycol 1000, or propylene glycol,~~ or mixtures thereof.

16(Previously Presented): The formulation according to claim 31, wherein the surfactant is polysorbate 20, polysorbate 80, a bile acid, lecithin, an ethoxylated vegetable oil, vitamin E, or polyoxyethylene-polyoxypropylene block copolymers.

17(Cancelled).

18(Previously Presented): The formulation according to claim 31, wherein the formulation comprises a concentration of CCI-779 from about 2.5 mg/mL to about 10 mg/mL.

19-30(Cancelled).

31(Previously Presented): A parenteral formulation which comprises
about 1 mg/mL to about 25 mg/mL rapamycin 42-ester with 3-
hydroxy-2-(hydroxymethyl)-2-methylpropionic acid (CCI-779),
about 10% to about 90% w/v of an alcoholic solvent,
0.001% to 0.5 % w/v of an antioxidant comprising d,l- α -tocopherol,
a diluent solvent, and
about 0.5% to about 10% w/v surfactant.

32(Previously Presented): The parenteral formulation according to claim
31, wherein the antioxidant further comprises citric acid and the alcoholic solvent is
ethanol.

33(Previously Presented): The parenteral formulation according to claim
31, comprising ethanol, citric acid, Vitamin E and propylene glycol.

34 (Previously Presented): The parenteral formulation according to claim
33, wherein the antioxidant is d,l- α -tocopherol.

35(Previously Presented): The parenteral formulation according to claim
31, wherein the antioxidant further comprises 0.01% w/v of citric acid.

36(Previously Presented): The parenteral formulation according to claim
31, wherein the antioxidant is a mixture of citric acid and d,l- α -tocopherol.

37(Previously Presented): The parenteral formulation according to claim
31, wherein the surfactant is selected from the group consisting of polysorbate 20,
polysorbate 80, PEG-35 castor oil, or mixtures thereof.

38(Previously Presented): A parenteral formulation which comprises about 10 mg/mL to about 25 mg/mL rapamycin 42-ester with 3-hydroxy-2-(hydroxymethyl)-2-methylpropionic acid (CCI-779), dehydrated ethanol, 0.01% to 0.5% w/v of an antioxidant comprising d,l- α -tocopherol, a diluent solvent comprising polyethylene glycol, and about 0.5% to about 10% w/v surfactant comprising polysorbate 80.

39(Previously Presented): The parenteral formulation according to claim 38, which comprises 0.075% w/v d,l- α -tocopherol.